Table 1 Demographics and baseline characteristics in patients with Ph+ CP CML by age and comorbidities.

From: Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

 

By age

By comorbidities

n (%)

<65 years

n = 95

65–74 years

n = 33

≥75 years

n = 28

mCCI 2

n = 99

mCCI 3

n = 27

mCCI ≥ 4

n = 30

Male

47 (49.5)

21 (63.6)

13 (46.4)

45 (45.5)

15 (55.6)

21 (70.0)

Age, median (range), years

51.0 (20.0–64.0)

69.0 (65.0–74.0)

78.0 (75.0–89.0)

53.0 (20.0–89.0)

67.0 (38.0–87.0)

71.0 (54.0–85.0)

ECOG PS

 0

70 (73.7)

23 (69.7)

13 (46.4)

73 (73.7)

15 (55.6)

18 (60.0)

 1

22 (23.2)

9 (27.3)

14 (50.0)

23 (23.2)

11 (40.7)

11 (36.7)

 2

3 (3.2)

1 (3.0)

1 (3.6)

3 (3.0)

1 (3.7)

1 (3.3)

Number of prior TKIs

 1

32 (33.7)

7 (21.2)

5 (17.9)

33 (33.3)

6 (22.2)

5 (16.7)

 2

31 (32.6)

15 (45.5)

14 (50.0)

37 (37.4)

11 (40.7)

12 (40.0)

 3

27 (28.4)

10 (30.3)

9 (32.1)

25 (25.3)

10 (37.0)

11 (36.7)

 4

5 (5.3)

1 (3.0)

0

4 (4.0)

0

2 (6.7)

Prior interferon alpha

8 (8.4)

2 (6.1)

1 (3.6)

6 (6.1)

3 (11.1)

2 (6.7)

Prior imatinib

81 (85.3)

32 (97.0)

28 (100.0)

87 (87.9)

25 (92.6)

29 (96.7)

Prior dasatinib

55 (57.9)

21 (63.6)

19 (67.9)

53 (53.5)

21 (77.8)

21 (70.0)

Prior nilotinib

51 (53.7)

16 (48.5)

12 (42.9)

52 (52.5)

9 (33.3)

18 (60.0)

Resistant to any prior TKI

49 (51.6)

21 (63.6)

12 (42.9)

51 (51.5)

16 (59.3)

15 (50.0)

Intolerant to all prior TKIs

46 (48.4)

12 (36.4)

16 (57.1)

48 (48.5)

11 (40.7)

15 (50.0)

  1. CML chronic myeloid leukemia, CP chronic phase, ECOG PS Eastern Cooperative Oncology Group performance score, mCCI Charlson Comorbidity Index without age component, Ph Philadelphia chromosome, TKI tyrosine kinase inhibitor.
Back to article page